2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1168

Eosinophilic Fasciitis: Baseline Retrospective Evaluation of Clinical Characteristics and Prognosis in a Cohort of 83 Patients
Abstract Number: 876

Epidemiologic Subsets Drive a Differentiated Clinical and Immunological Presentation of Primary Sjögren Syndrome: Analysis of 9302 Patients from the Big Data International Sjögren Cohort
Abstract Number: 209

Epidemiologic Subsets Drive a Differentiated Thoracic and Extrathoracic Presentation of Sarcoidosis: Analysis of 1082 Patients from the Sarcogeas-SEMI Registry
Abstract Number: 806

Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database
Abstract Number: 982

Epidemiology and Mortality in Systemic Sclerosis in South Korea: A Nationwide Population-Based Study
Abstract Number: 2681

Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome
Abstract Number: 13

Epidemiology of Antiphospholipid Syndrome: A Population-Based Study
Abstract Number: 1885

Epidemiology of Hospitalized Adult Onset Still’s Disease in United States
Abstract Number: 2105

Epidemiology of Interstitial Pneumonia with Autoimmune Features
Abstract Number: 2830

Epigenetic Cell Counting: A Novel Tool to Quantify Immune Cells in Salivary Glands Detects Robust Correlations of T Follicular Helper Cells with Immunopathology
Abstract Number: 1379

Epithelial Neutrophil-Activating Peptide 78/C-X-C Motif Chemokine 5 in the Insulin Resistance of Patients with Rheumatoid Arthritis
Abstract Number: 2647

Epstein Barr Virus Interluekin-10 (vIL10) in Systemic Lupus Erythematosus
Abstract Number: 2428

Epstein-Barr Virus Infection and Epstein-Barr Virus　Nuclear Antigen 1 Variants in the Synovial Tissue of Rheumatoid Arthritis
Abstract Number: 2221

Eradication of Hepatitis C Among US Veterans: Examination of Changes in Pain Severity and Prescription Opioid Use Following Treatment
Abstract Number: 1910

ERAP1 Deficiency Implicates Long Peptides in Protection from HLA-B27-Induced Experimental Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].